CDK4 and Thrombocytopenia: It is worth noting that when abemaciclib was added to endocrine therapy, it was associated with a higher frequency of vomiting, diarrhoea, thrombocytopenia, and increased transaminases compared with other cyclin-dependent kinase 4 and 6 inhibitors.